-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tisagenlecleucel in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tisagenlecleucel in Primary CNS Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tisagenlecleucel in Primary CNS Lymphoma Drug Details: Tisagenlecleucel (Kymriah) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tafasitamab in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tafasitamab in Primary CNS Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tafasitamab in Primary CNS Lymphoma Drug Details: Tafasitamab (Monjuvi / Minjuvi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abemaciclib in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Primary CNS Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abemaciclib in Primary CNS Lymphoma Drug Details: Abemaciclib (Verzenio / Verzenios...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Primary CNS Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Primary CNS Lymphoma Drug Details: Pembrolizumab (Keytruda) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CN-201 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CN-201 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CN-201 in Follicular Lymphoma Drug Details: CN-201 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Primary CNS Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Primary CNS Lymphoma Drug Details: Ibrutinib (Imbruvica) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Primary CNS Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Primary CNS Lymphoma Drug Details: Lisocabtagene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golcadomide Hydrochloride in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golcadomide Hydrochloride in Primary CNS Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golcadomide Hydrochloride in Primary CNS Lymphoma Drug Details: Golcadomide...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CN-201 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CN-201 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CN-201 in Mantle Cell Lymphoma Drug Details: CN-201 is under development...